The quest for the ideal NASH biomarker
- PMID: 36958368
- DOI: 10.1016/S2468-1253(23)00063-8
The quest for the ideal NASH biomarker
Conflict of interest statement
GS has been a speaker for Merck, Gilead, AbbVie, Novonordisk, and Pfizer; has been an advisory board member for Pfizer, Merck, Novonordisk, Gilead, and Intercept; and has received unrestricted research funding from Theratechnologies. She is supported by a Senior Salary Award from Fonds de Recherche du Quebec—Sante (296306).
Comment on
-
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.Lancet Gastroenterol Hepatol. 2023 Aug;8(8):714-725. doi: 10.1016/S2468-1253(23)00017-1. Epub 2023 Mar 21. Lancet Gastroenterol Hepatol. 2023. PMID: 36958367
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical